Tortoise Investment Management, LLC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 172 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2015. The put-call ratio across all filers is 1.39 and the average weighting 0.2%.

Quarter-by-quarter ownership
Tortoise Investment Management, LLC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$30,124
-22.7%
8450.0%0.00%
-33.3%
Q2 2023$38,980
+15.0%
8450.0%0.01%
+20.0%
Q1 2023$33,885
-13.4%
8450.0%0.01%
-28.6%
Q4 2022$39,149
+11.9%
8450.0%0.01%0.0%
Q3 2022$35,000
-30.0%
8450.0%0.01%
-30.0%
Q2 2022$50,000
-18.0%
8450.0%0.01%
-9.1%
Q1 2022$61,000
-14.1%
8450.0%0.01%
-15.4%
Q4 2021$71,000
-6.6%
8450.0%0.01%
-13.3%
Q3 2021$76,000
-6.2%
8450.0%0.02%
-11.8%
Q2 2021$81,000
-25.0%
845
-10.6%
0.02%
-29.2%
Q1 2021$108,000
-17.6%
9450.0%0.02%
-20.0%
Q4 2020$131,000
+52.3%
945
-9.6%
0.03%
+42.9%
Q3 2020$86,000
+4.9%
1,0450.0%0.02%0.0%
Q2 2020$82,000
+78.3%
1,0450.0%0.02%
+61.5%
Q1 2020$46,000
+2.2%
1,0450.0%0.01%
+18.2%
Q4 2019$45,0000.0%1,0450.0%0.01%
-8.3%
Q3 2019$45,000
-31.8%
1,0450.0%0.01%
-29.4%
Q2 2019$66,000
-8.3%
1,0450.0%0.02%
-10.5%
Q1 2019$72,000
+60.0%
1,0450.0%0.02%
+58.3%
Q4 2018$45,000
-43.8%
1,0450.0%0.01%
-42.9%
Q3 2018$80,0000.0%1,0450.0%0.02%
-4.5%
Q2 2018$80,000
+50.9%
1,0450.0%0.02%
+46.7%
Q1 2018$53,000
+10.4%
1,0450.0%0.02%
+7.1%
Q4 2017$48,000
-14.3%
1,0450.0%0.01%
-17.6%
Q3 2017$56,000
-13.8%
1,0450.0%0.02%
-19.0%
Q2 2017$65,000
+1.6%
1,045
+10.6%
0.02%0.0%
Q1 2017$64,000
-16.9%
945
-13.7%
0.02%
-22.2%
Q4 2016$77,000
-1.3%
1,0950.0%0.03%
+3.8%
Q3 2016$78,000
+44.4%
1,0950.0%0.03%
+36.8%
Q2 2016$54,000
-21.7%
1,0950.0%0.02%
-24.0%
Q1 2016$69,000
-34.9%
1,095
+15.9%
0.02%
-34.2%
Q4 2015$106,000
+16.5%
9450.0%0.04%
+8.6%
Q3 2015$91,000
-24.2%
945
-19.6%
0.04%
-22.2%
Q2 2015$120,000
+12.1%
1,175
-32.0%
0.04%
+9.8%
Q1 2015$107,000
+40.8%
1,7280.0%0.04%
+36.7%
Q4 2014$76,000
-22.4%
1,7280.0%0.03%
-26.8%
Q3 2014$98,0001,7280.04%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2015
NameSharesValueWeighting ↓
First Light Asset Management, LLC 213,887$29,608,0002.19%
Rock Springs Capital Management LP 566,500$78,421,0001.66%
FEDERATED HERMES, INC. 4,280,528$592,554,0001.21%
AtonRa Partners 17,646$2,443,0001.20%
EMERALD MUTUAL FUND ADVISERS TRUST 218,390$30,232,0001.05%
EMERALD ADVISERS, LLC 226,875$31,406,0001.04%
Atika Capital Management LLC 89,000$12,319,0000.96%
Capital Impact Advisors, LLC 25,582$3,541,0000.87%
JGP Global Gestao de Recursos Ltda. 1,586$220,0000.83%
CAPITAL INTERNATIONAL LTD /CA/ 79,742$11,039,0000.64%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders